IL2 and autoimmune disease: With low dose and mutein IL-2 therapy currently advancing through clinical trials as a method for in vivo Treg expansion in autoimmune diseases and transplantation,13,75,76 there is now an attractive argument for exploring IL-33 therapy for the same indications.